ScinoPharm Taiwan Ltd (台灣神隆), which makes active pharmaceutical ingredients (API), yesterday said that net income last quarter declined 32 percent year-on-year to NT$132 million (US$4.15 million), or NT$0.19 per share, due to steep drops in shipments of generic weight-loss and antidepressant drugs.
Reduced sales led to diminished capacity utilization, which further eroded earnings, ScinoPharm said.
“Unlike last year, shipments of weight-loss and antidepressant drugs were virtually halted during the first half, but we expect shipment growth to resume in the second half,” ScinoPharm chief financial officer Patricia Chou (周珮芬) told an investors’ conference.
Despite the profit decline, gross margin last quarter improved to 38 percent from 35 percent in the January-to-March period, which Chou said was an indication that the company’s earnings have begun stabilizing.
“The company is seeking other API clients to replace reduced orders for branded drugs,” she said, adding that there is a lot of room for improvement before ScinoPharm regains the 40 percent gross margin it enjoyed before last year.
Operating expenses last quarter dropped 17 percent, due to reductions in payroll and bonuses and other cost-control measures, Chou said.
However, the company did not reduce research and development expenses in the quarter, she added.
Net income in the first half fell 32 percent year-on-year to NT$245 million, or NT$0.35 per share, as sales slid 13 percent to NT$1.94 billion and gross margin fell to 37 percent from 42 percent.
ScinoPharm’s core competence lies in its oncology drugs because of the high entry barrier in the market. Overall sales by products showed that oncology drugs accounted for 79 percent of overall sales in the first half, compared with 65 percent last year.
By business, generics manufacturing contributed about 89 percent to overall sales in the first six months, compared with 77 percent last year, the company said.
For the second half, the company said it would begin to focus on China and Japan, which offer faster growth opportunities, compared with slowing growth in the US and Europe, where opportunities are further constrained by large-scale mergers and acquisitions in the pharmaceuticals sector.
ScinoPharm also reported an important milestone in its drive to expand into the lower segments of the pharmaceutical supply chain.
The company said that it recently submitted an abbreviated new drug application (ANDA) to the US Food and Drug Administration for fondaparinux, which is an anti-thrombotic agent used to prevent the occurrence of blood clots after surgery.
The ANDA phase might take two to three months to complete, ScinoPharm said.
Among the rows of vibrators, rubber torsos and leather harnesses at a Chinese sex toys exhibition in Shanghai this weekend, the beginnings of an artificial intelligence (AI)-driven shift in the industry quietly pulsed. China manufactures about 70 percent of the world’s sex toys, most of it the “hardware” on display at the fair — whether that be technicolor tentacled dildos or hyper-realistic personalized silicone dolls. Yet smart toys have been rising in popularity for some time. Many major European and US brands already offer tech-enhanced products that can enable long-distance love, monitor well-being and even bring people one step closer to
Malaysia’s leader yesterday announced plans to build a massive semiconductor design park, aiming to boost the Southeast Asian nation’s role in the global chip industry. A prominent player in the semiconductor industry for decades, Malaysia accounts for an estimated 13 percent of global back-end manufacturing, according to German tech giant Bosch. Now it wants to go beyond production and emerge as a chip design powerhouse too, Malaysian Prime Minister Anwar Ibrahim said. “I am pleased to announce the largest IC (integrated circuit) Design Park in Southeast Asia, that will house world-class anchor tenants and collaborate with global companies such as Arm [Holdings PLC],”
Sales in the retail, and food and beverage sectors last month continued to rise, increasing 0.7 percent and 13.6 percent respectively from a year earlier, setting record highs for the month of March, the Ministry of Economic Affairs said yesterday. Sales in the wholesale sector also grew last month by 4.6 annually, mainly due to the business opportunities for emerging applications related to artificial intelligence (AI) and high-performance computing technologies, the ministry said in a report. The ministry forecast that retail, and food and beverage sales this month would retain their growth momentum as the former would benefit from Tomb Sweeping Day
Thousands of parents in Singapore are furious after a Cordlife Group Ltd (康盛人生集團), a major operator of cord blood banks in Asia, irreparably damaged their children’s samples through improper handling, with some now pursuing legal action. The ongoing case, one of the worst to hit the largely untested industry, has renewed concerns over companies marketing themselves to anxious parents with mostly unproven assurances. This has implications across the region, given Cordlife’s operations in Hong Kong, Macau, Indonesia, the Philippines and India. The parents paid for years to have their infants’ cord blood stored, with the understanding that the stem cells they contained